![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Molecular Pharmacology, Vol 16, 687-699, Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics
1 Departments of Pharmacology and Experimental Therapeutics, and Psychiatry and Behavioral Sciences,
Johns Hopkins University School of Medicine, Baltimore, Maryland 21205
[3H]5-Hydroxytryptamine (5-HT), [3H]lysergic acid diethylamide (LSD) and [3H]spiroperidol bind to membranes from the rat frontal cerebral cortex in a manner indicating a selective interaction with serotonin receptors. Differential drug potencies in competing for [3H]5-HT and [3H]spiroperidol binding sites suggest that these two [3H]ligands respectively label two distinct populations of receptors, while [3H]LSD labels both the [3H]5-HT and [3H]spiroperidol sites. After incubation of brain membranes with 30 nM spiroperidol, drug specificity of the residual [3H]LSD binding resembles that of receptors labeled by [3H]5-HT. Conversely, drug effects on [3H]LSD binding in the presence of 300 nM 5-HT resemble effects with [3H]spiroperidol. We propose that [3H]5-HT and [3H]-spiroperidol label distinct populations of serotonin receptors in rat brain, designated 5-HT1 and 5-HT2 receptors, respectively. [3H]LSD appears to bind to both receptors to a similar extent.
Note:
ACKNOWLEDGMENTS
We thank Richard M. Lebovitz for his skillful technical assistance and Pamela Morgan for manuscript
preparation.
This article has been cited by other articles:
|
|
 |
|
  S. W. Watts The beginning of a fantastic, unanswered question: is 5-HT involved in systemic hypertension? Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H915 - H916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Dumitriu, J. E. Cohen, Q. Wan, A. M. Negroiu, and T. W. Abrams Serotonin Receptor Antagonists Discriminate Between PKA- and PKC-Mediated Plasticity in Aplysia Sensory Neurons J Neurophysiol, April 1, 2006; 95(4): 2713 - 2720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Puig, F. Artigas, and P. Celada Modulation of the Activity of Pyramidal Neurons in Rat Prefrontal Cortex by Raphe Stimulation In Vivo: Involvement of Serotonin and GABA Cereb Cortex, January 1, 2005; 15(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Stocker, L. De Franceschi, G. A. McNaughton-Smith, R. Corrocher, Y. Beuzard, and C. Brugnara ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice Blood, March 15, 2003; 101(6): 2412 - 2418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. S. Shum, J. A. Melendez, and J. J. Jeffrey Serotonin-induced MMP-13 Production Is Mediated via Phospholipase C, Protein Kinase C, and ERK1/2 in Rat Uterine Smooth Muscle Cells J. Biol. Chem., November 1, 2002; 277(45): 42830 - 42840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Lopez-Gimenez, M. Villazon, J. Brea, M. I. Loza, J. M. Palacios, G. Mengod, and M. T. Vilaro Multiple Conformations of Native and Recombinant Human 5-Hydroxytryptamine2A Receptors Are Labeled by Agonists and Discriminated by Antagonists Mol. Pharmacol., October 1, 2001; 60(4): 690 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Hwang and N. J. Dun 5-Hydroxytryptamine Responses in Immature Rat Rostral Ventrolateral Medulla Neurons In Vitro J Neurophysiol, September 1, 1998; 80(3): 1033 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yates and I.N. Ferrier 5-HT1A Receptors in major depression J Psychopharmacol, January 1, 1990; 4(2): 69 - 74. [Abstract] [PDF]
|
|
|
|
|
|
C.T. Dourish, G.A. Kennett, and G. Curzon The 5-HT1A agonists 8-OH-DPAT, buspirone and ipsapirone attenuate stress-induced anorexia in rats J Psychopharmacol, January 1, 1987; 1(1): 23 - 30. [Abstract] [PDF]
|
|
|
|
|
|
M.D. Tricklebank Subtypes of 5-HT receptors J Psychopharmacol, January 1, 1987; 1(4): 222 - 226. [PDF]
|
|
|
|
 |
|
 C. Altar, S O'Neil, R. Walter Jr, and J. Marshall Brain dopamine and serotonin receptor sites revealed by digital subtraction autoradiography Science, May 3, 1985; 228(4699): 597 - 600. [Abstract] [PDF]
|
|
|
|
|
|
H. Wagner Jr, H. Burns, R. Dannals, D. Wong, B Langstrom, T Duelfer, J. Frost, H. Ravert, J. Links, S. Rosenbloom, et al. Imaging dopamine receptors in the human brain by positron tomography Science, September 23, 1983; 221(4617): 1264 - 1266. [Abstract] [PDF]
|
|
|
|
|
|
S. Treiser, C. Cascio, T. O'Donohue, N. Thoa, D. Jacobowitz, and K. Kellar Lithium increases serotonin release and decreases serotonin receptors in the hippocampus Science, September 25, 1981; 213(4515): 1529 - 1531. [Abstract] [PDF]
|
|
|
|
|
|
S. Peroutka, R. Lebovitz, and S. Snyder Two distinct central serotonin receptors with different physiological functions Science, May 15, 1981; 212(4496): 827 - 829. [Abstract] [PDF]
|
|
|
|
|
|
D. Kendall, G. Stancel, and S. Enna Imipramine: effect of ovarian steroids on modifications in serotonin receptor binding Science, March 13, 1981; 211(4487): 1183 - 1185. [Abstract] [PDF]
|
|
|
|
 |
|
 J. De Cree, J. Leempoels, W. De Cock, H. Geukens, and H. Verhaegen The Antihypertensive Effects of a Pure and Selective Serotonin-Receptor Blocking Agent (R 41 468) in Elderly Patients Angiology, February 1, 1981; 32(2): 137 - 144. [Abstract] [PDF]
|
|
|
|
|
|
S. Peroutka and S. Snyder Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding Science, October 3, 1980; 210(4465): 88 - 90. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
